关注
David Balli
David Balli
Advaxis
在 fastmail.com 的电子邮件经过验证
标题
引用次数
引用次数
年份
Neoadjuvant nivolumab plus chemotherapy in resectable lung cancer
PM Forde, J Spicer, S Lu, M Provencio, T Mitsudomi, MM Awad, E Felip, ...
New England Journal of Medicine 386 (21), 1973-1985, 2022
14272022
EMT subtype influences epithelial plasticity and mode of cell migration
NM Aiello, R Maddipati, RJ Norgard, D Balli, J Li, S Yuan, T Yamazoe, ...
Developmental cell 45 (6), 681-695. e4, 2018
6212018
Tumor cell-intrinsic factors underlie heterogeneity of immune cell infiltration and response to immunotherapy
J Li, KT Byrne, F Yan, T Yamazoe, Z Chen, T Baslan, LP Richman, JH Lin, ...
Immunity 49 (1), 178-193. e7, 2018
6022018
Key parameters of tumor epitope immunogenicity revealed through a consortium approach improve neoantigen prediction
DK Wells, MM van Buuren, KK Dang, VM Hubbard-Lucey, KCF Sheehan, ...
Cell 183 (3), 818-834. e13, 2020
3732020
Detection of therapeutically targetable driver and resistance mutations in lung cancer patients by next-generation sequencing of cell-free circulating tumor DNA
JC Thompson, SS Yee, AB Troxel, SL Savitch, R Fan, D Balli, ...
Clinical Cancer Research 22 (23), 5772-5782, 2016
3642016
Immune cytolytic activity stratifies molecular subsets of human pancreatic cancer
D Balli, AJ Rech, BZ Stanger, RH Vonderheide
Clinical Cancer Research 23 (12), 3129-3138, 2017
2342017
Foxm1 transcription factor is required for lung fibrosis and epithelial‐to‐mesenchymal transition
D Balli, V Ustiyan, Y Zhang, IC Wang, AJ Masino, X Ren, JA Whitsett, ...
The EMBO journal 32 (2), 231-244, 2013
1812013
First-line nivolumab plus ipilimumab versus chemotherapy in patients with unresectable malignant pleural mesothelioma: 3-year outcomes from CheckMate 743
S Peters, A Scherpereel, R Cornelissen, Y Oulkhouir, L Greillier, ...
Annals of oncology 33 (5), 488-499, 2022
1572022
Foxm1 transcription factor is required for macrophage migration during lung inflammation and tumor formation
D Balli, X Ren, FS Chou, E Cross, Y Zhang, VV Kalinichenko, TV Kalin
Oncogene 31 (34), 3875-3888, 2012
942012
Tumor immunity and survival as a function of alternative neopeptides in human cancer
AJ Rech, D Balli, A Mantero, H Ishwaran, KL Nathanson, BZ Stanger, ...
Cancer immunology research 6 (3), 276-287, 2018
842018
Deletion of Forkhead Box M1 transcription factor from respiratory epithelial cells inhibits pulmonary tumorigenesis
IC Wang, L Meliton, X Ren, Y Zhang, D Balli, J Snyder, JA Whitsett, ...
PloS one 4 (8), e6609, 2009
822009
Endothelial cell–specific deletion of transcription factor FoxM1 increases urethane-induced lung carcinogenesis
D Balli, Y Zhang, J Snyder, VV Kalinichenko, TV Kalin
Cancer research 71 (1), 40-50, 2011
762011
Foxm1 expression in prostate epithelial cells is essential for prostate carcinogenesis
Y Cai, D Balli, V Ustiyan, L Fulford, A Hiller, V Misetic, Y Zhang, ...
Journal of Biological Chemistry 288 (31), 22527-22541, 2013
722013
An integrated flow cytometry-based platform for isolation and molecular characterization of circulating tumor single cells and clusters
N Bhagwat, K Dulmage, CH Pletcher Jr, L Wang, W DeMuth, M Sen, ...
Scientific reports 8 (1), 5035, 2018
682018
FOXM1 activates AGR2 and causes progression of lung adenomas into invasive mucinous adenocarcinomas
D Milewski, D Balli, V Ustiyan, T Le, H Dienemann, A Warth, K Breuhahn, ...
PLoS genetics 13 (12), e1007097, 2017
602017
First-line nivolumab plus ipilimumab with chemotherapy versus chemotherapy alone for metastatic NSCLC in CheckMate 9LA: 3-year clinical update and outcomes in patients with …
LG Paz-Ares, TE Ciuleanu, M Cobo, J Bennouna, M Schenker, Y Cheng, ...
Journal of Thoracic Oncology 18 (2), 204-222, 2023
572023
MYC Levels Regulate Metastatic Heterogeneity in Pancreatic Adenocarcinoma
R Maddipati, RJ Norgard, T Baslan, KS Rathi, A Zhang, A Saeid, ...
Cancer discovery 12 (2), 542-561, 2022
522022
Loss of FOXM1 in macrophages promotes pulmonary fibrosis by activating p38 MAPK signaling pathway
C Goda, D Balli, M Black, D Milewski, T Le, V Ustiyan, X Ren, ...
PLoS Genetics 16 (4), e1008692, 2020
462020
84O Neoadjuvant nivolumab (N)+ platinum-doublet chemotherapy (C) for resectable NSCLC: 3-y update from CheckMate 816
PM Forde, J Spicer, N Girard, M Provencio, S Lu, C Wang, M Awad, ...
Journal of Thoracic Oncology 18 (4), S89-S90, 2023
422023
Calcium signaling induces a partial EMT
RJ Norgard, JR Pitarresi, R Maddipati, NM Aiello‐Couzo, D Balli, J Li, ...
EMBO reports 22 (9), e51872, 2021
402021
系统目前无法执行此操作,请稍后再试。
文章 1–20